Skip to content
Themes / Biopharma & Biosimilars

Biopharma & Biosimilars

Biologics, biosimilars, vaccines, advanced therapies, and biopharma development services.

BiopharmaAuto-built
Theme price path

Biopharma & Biosimilars vs Nifty 500

Weekly basket performance over the latest 52 observations. Green is ahead of Nifty 500; red is behind.

Through 09 Oct 2026
Coverage healthy
Theme aheadTheme behindNifty 500Base 100 at the first visible weekLatest: Outperforming +19.2%
849410311212117 Oct 2025 | Biopharma & Biosimilars 100.0 | Nifty 500 100.0 | In line 0.0% | breadth 25% | coverage 100%24 Oct 2025 | Biopharma & Biosimilars 101.0 | Nifty 500 100.4 | Outperforming +0.6% | breadth 75% | coverage 100%31 Oct 2025 | Biopharma & Biosimilars 100.3 | Nifty 500 100.5 | Underperforming -0.2% | breadth 38% | coverage 100%07 Nov 2025 | Biopharma & Biosimilars 98.8 | Nifty 500 99.7 | Underperforming -0.9% | breadth 38% | coverage 100%14 Nov 2025 | Biopharma & Biosimilars 101.7 | Nifty 500 101.0 | Outperforming +0.7% | breadth 75% | coverage 100%21 Nov 2025 | Biopharma & Biosimilars 96.9 | Nifty 500 100.8 | Underperforming -3.9% | breadth 0% | coverage 100%28 Nov 2025 | Biopharma & Biosimilars 97.6 | Nifty 500 101.4 | Underperforming -3.7% | breadth 75% | coverage 100%05 Dec 2025 | Biopharma & Biosimilars 97.3 | Nifty 500 101.0 | Underperforming -3.7% | breadth 25% | coverage 100%12 Dec 2025 | Biopharma & Biosimilars 97.3 | Nifty 500 100.5 | Underperforming -3.2% | breadth 38% | coverage 100%19 Dec 2025 | Biopharma & Biosimilars 98.1 | Nifty 500 100.3 | Underperforming -2.2% | breadth 50% | coverage 100%26 Dec 2025 | Biopharma & Biosimilars 99.5 | Nifty 500 100.8 | Underperforming -1.3% | breadth 38% | coverage 100%02 Jan 2026 | Biopharma & Biosimilars 99.0 | Nifty 500 102.1 | Underperforming -3.0% | breadth 50% | coverage 100%09 Jan 2026 | Biopharma & Biosimilars 97.0 | Nifty 500 99.4 | Underperforming -2.4% | breadth 13% | coverage 100%16 Jan 2026 | Biopharma & Biosimilars 95.4 | Nifty 500 99.5 | Underperforming -4.1% | breadth 13% | coverage 100%23 Jan 2026 | Biopharma & Biosimilars 89.5 | Nifty 500 96.2 | Underperforming -7.0% | breadth 25% | coverage 100%01 Feb 2026 | Biopharma & Biosimilars 88.0 | Nifty 500 95.8 | Underperforming -8.1% | breadth 63% | coverage 100%06 Feb 2026 | Biopharma & Biosimilars 87.5 | Nifty 500 99.3 | Underperforming -11.9% | breadth 38% | coverage 100%13 Feb 2026 | Biopharma & Biosimilars 88.2 | Nifty 500 98.8 | Underperforming -10.7% | breadth 63% | coverage 100%20 Feb 2026 | Biopharma & Biosimilars 89.3 | Nifty 500 99.1 | Underperforming -9.9% | breadth 63% | coverage 100%27 Feb 2026 | Biopharma & Biosimilars 90.6 | Nifty 500 98.2 | Underperforming -7.7% | breadth 75% | coverage 100%06 Mar 2026 | Biopharma & Biosimilars 90.8 | Nifty 500 95.3 | Underperforming -4.7% | breadth 50% | coverage 100%13 Mar 2026 | Biopharma & Biosimilars 91.1 | Nifty 500 90.6 | Outperforming +0.6% | breadth 50% | coverage 100%20 Mar 2026 | Biopharma & Biosimilars 91.0 | Nifty 500 90.4 | Outperforming +0.7% | breadth 38% | coverage 100%27 Mar 2026 | Biopharma & Biosimilars 91.3 | Nifty 500 89.1 | Outperforming +2.5% | breadth 50% | coverage 100%02 Apr 2026 | Biopharma & Biosimilars 90.4 | Nifty 500 88.7 | Outperforming +1.9% | breadth 38% | coverage 100%10 Apr 2026 | Biopharma & Biosimilars 92.9 | Nifty 500 94.7 | Underperforming -1.9% | breadth 88% | coverage 100%17 Apr 2026 | Biopharma & Biosimilars 96.5 | Nifty 500 96.9 | Underperforming -0.4% | breadth 88% | coverage 100%24 Apr 2026 | Biopharma & Biosimilars 99.3 | Nifty 500 95.6 | Outperforming +3.9% | breadth 63% | coverage 100%30 Apr 2026 | Biopharma & Biosimilars 99.3 | Nifty 500 96.1 | Outperforming +3.3% | breadth 38% | coverage 100%08 May 2026 | Biopharma & Biosimilars 103.6 | Nifty 500 98.0 | Outperforming +5.7% | breadth 75% | coverage 100%15 May 2026 | Biopharma & Biosimilars 108.0 | Nifty 500 95.5 | Outperforming +13.1% | breadth 63% | coverage 100%22 May 2026 | Biopharma & Biosimilars 109.3 | Nifty 500 96.0 | Outperforming +13.9% | breadth 63% | coverage 100%29 May 2026 | Biopharma & Biosimilars 108.8 | Nifty 500 96.0 | Outperforming +13.3% | breadth 25% | coverage 100%05 Jun 2026 | Biopharma & Biosimilars 113.2 | Nifty 500 95.2 | Outperforming +18.9% | breadth 50% | coverage 100%12 Jun 2026 | Biopharma & Biosimilars 113.2 | Nifty 500 95.8 | Outperforming +18.2% | breadth 63% | coverage 100%19 Jun 2026 | Biopharma & Biosimilars 112.4 | Nifty 500 98.2 | Outperforming +14.5% | breadth 38% | coverage 100%26 Jun 2026 | Biopharma & Biosimilars 114.7 | Nifty 500 97.9 | Outperforming +17.2% | breadth 75% | coverage 100%03 Jul 2026 | Biopharma & Biosimilars 118.4 | Nifty 500 98.7 | Outperforming +20.0% | breadth 88% | coverage 100%10 Jul 2026 | Biopharma & Biosimilars 115.6 | Nifty 500 99.0 | Outperforming +16.8% | breadth 25% | coverage 100%17 Jul 2026 | Biopharma & Biosimilars 115.5 | Nifty 500 98.9 | Outperforming +16.8% | breadth 38% | coverage 100%24 Jul 2026 | Biopharma & Biosimilars 110.7 | Nifty 500 97.2 | Outperforming +13.9% | breadth 13% | coverage 100%31 Jul 2026 | Biopharma & Biosimilars 109.6 | Nifty 500 99.4 | Outperforming +10.3% | breadth 38% | coverage 100%07 Aug 2026 | Biopharma & Biosimilars 113.7 | Nifty 500 100.5 | Outperforming +13.1% | breadth 63% | coverage 100%14 Aug 2026 | Biopharma & Biosimilars 114.1 | Nifty 500 100.0 | Outperforming +14.1% | breadth 38% | coverage 100%21 Aug 2026 | Biopharma & Biosimilars 113.9 | Nifty 500 99.6 | Outperforming +14.4% | breadth 25% | coverage 100%28 Aug 2026 | Biopharma & Biosimilars 115.8 | Nifty 500 99.7 | Outperforming +16.1% | breadth 50% | coverage 100%04 Sept 2026 | Biopharma & Biosimilars 114.4 | Nifty 500 98.5 | Outperforming +16.1% | breadth 38% | coverage 100%11 Sept 2026 | Biopharma & Biosimilars 115.2 | Nifty 500 96.9 | Outperforming +18.9% | breadth 50% | coverage 100%18 Sept 2026 | Biopharma & Biosimilars 115.5 | Nifty 500 96.8 | Outperforming +19.3% | breadth 63% | coverage 100%25 Sept 2026 | Biopharma & Biosimilars 116.5 | Nifty 500 95.8 | Outperforming +21.6% | breadth 63% | coverage 100%01 Oct 2026 | Biopharma & Biosimilars 113.8 | Nifty 500 92.6 | Outperforming +22.9% | breadth 25% | coverage 100%09 Oct 2026 | Biopharma & Biosimilars 110.5 | Nifty 500 92.7 | Outperforming +19.2% | breadth 13% | coverage 100%Outperforming +19.2%17 Oct 202510 Apr 202609 Oct 2026
Theme return
+10.5%
Nifty 500
-7.3%
Vs Nifty 500
+19.2%
Latest coverage
8/8
How this plot is calculated

The theme line is green when its cumulative rebased performance is above Nifty 500 and red when it is below. The chart callout shows the latest relative performance as the theme level divided by the benchmark level, minus one.

The basket uses the theme's current reviewed companies. For each available week, we calculate every valid constituent's close-to-close return and give each company the same weight. If a weekly rollup is missing or lags the daily series, the final available daily close in that week is used.

For baskets with at least 10 valid stocks, the highest and lowest 5% of weekly returns are trimmed to reduce split, corporate-action, and single-stock distortions. Weekly basket returns are then compounded and rebased to 100 beside the Nifty 500.

Breadth is the share of valid constituents that rose that week. Coverage is the number with usable aligned prices divided by current membership. Weekly moves above 80% are excluded as likely data or corporate-action outliers.

Limitation: this is a current-membership historical reconstruction, not a point-in-time investable index. It can contain survivorship bias and excludes costs, liquidity impact, dividends, and rebalancing turnover.

Model note: Current-member weekly equal-weight returns (5% tails trimmed for baskets of 10+), compounded and rebased to 100 against Nifty 500; lagging weekly rollups are patched with the final available daily close, and rotation uses 13-week excess return with four-week acceleration.

Theme scorecard

Measures whether this idea is investable today by blending cohort quality, valuation cushion, and price momentum. It is a research filter, not advice.

Build portfolio from this theme
Theme
19
Stretched
Quality
2
Valuation
23
Momentum
51
Positive MoS
25%
P/E 86.3 · ROCE 9%
Curated research view

Biopharma & Biosimilars

A focused investor view: high-conviction names first, then small/micro exposure only as controlled satellite risk. Live U-Score and MoS still come from the current database.

66/100
Theme score
Selective
Investability
35.5
Live avg U
-688.0%
Live avg MoS

Curated company map

Names from the curated theme note. Solid chips are present in the live eligible cohort; dashed chips need membership review, ticker verification, or may be indirect/unlisted exposure.

7/7 live eligible

Investment thesis

Biologics, biosimilars, vaccines, advanced therapies, and specialist development services offer higher barriers than conventional generics but require sustained research and regulatory execution.

1-2 year outlook: Long-duration positive, with position sizes tied to commercial proof rather than pipeline narratives alone.
Recommended allocation: 3-6%.

Key triggers

  • Product approvals
  • Biosimilar launches
  • Clinical milestones
  • Biopharma outsourcing wins

Major risks

  • Clinical failure
  • Regulatory delays
  • Large R&D outlays
  • Customer and product concentration
Small, micro, and SME names should be opt-in exposure. Suggested filters: U-Score above 65, positive MoS, Piotroski 7+, debt/equity below 0.8, promoter pledge below 10%, and enough traded value to exit without slippage.

Thesis

A disclosure-reviewed cohort for companies with operating exposure to biologics, biosimilars, vaccines, advanced therapies, or biopharma research and manufacturing services. It is intentionally narrower than the broad Pharma theme.

  • ▸Biopharma SHAKTI and import substitution
  • ▸Complex development and manufacturing barriers
  • ▸Clinical, regulatory, and concentration risk

Top picks · ranked by U-Score within this cohort

Full cohort

The rationale above is editorial — the ranking uses our U-Score engine so the names you see first are the strongest fundamentals fit, not the most popular or most-mentioned. Re-rank yourself if you weigh valuation or quality differently. All information is for study purposes only — consult your financial advisor before investing.